P. Cannell

发表

Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study

Matthew P Wright, R. Herrmann, K. Shaw, 2012, International Journal of Hematology.

Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.

W. Hiddemann, J. Radford, R. Marcus, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase III randomized trial of high‐dose CEOP + filgrastim versus standard‐dose CEOP in patients with non‐Hodgkin lymphoma: 10‐year follow‐up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial

P. Marlton, J. Matthews, P. Browett, 2014, American journal of hematology.

The thrombotic thrombocytopenic purpura registry: a new national resource to inform patient care and medical research

J. McNeil, E. Wood, S. Opat, 2009, Internal medicine journal.

Letter to the Editor Regarding "Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: A Systematic Review and Meta-Analysis".

M. Nikpour, J. Roddy, A. Calderone, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Autologous stem cell transplantation in systemic sclerosis: a systematic review.

M. Nikpour, J. Roddy, A. Calderone, 2017, Clinical and experimental rheumatology.

Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia

J. Matthews, A. Schwarer, D. Gill, 2001, Leukemia.

N. Kröger, J. Sierra, M. Robin, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic hematopoietic stem cell transplantation recipients have defects of both switched and igm memory B cells.

Matthew P Wright, F. Christiansen, C. Witt, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A phase II study of Rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation

M. Handel, S. Milliken, R. Will, 2004, Bone Marrow Transplantation.

Rheumatoid arthritis A phase II study of Rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation

M. Handel, J. Moore, S. Milliken, 2004 .

Early cessation of a randomised study in acute graft versus host disease: upfront mesenchymal stromal cells with corticosteroids versus corticosteroids alone

R. Herrmann, D. Purtill, M. Sturm, 2020, Bone Marrow Transplantation.

Deletion of CBFB in a patient with acute myelomonocytic leukemia (AML M4Eo) and inversion 16.

R. Herrmann, J. O'Reilly, L. Chipper, 2004, Cancer genetics and cytogenetics.

Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia

J. Reynolds, L. Chong, P. Browett, 2012, Haematologica.

Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia.

L. Campbell, J. Szer, I. Lewis, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of intensive induction and consolidation chemotherapy with idarubicin and high dose cytarabine on minimal residual disease levels in newly diagnosed adult precursor-B acute lymphoblastic leukemia☆

K. Byth, A. Morley, J. Szer, 2016, Contemporary clinical trials communications.

The use of IgH fingerprinting and ASO‐dependent PCR for the investigation of residual disease (MRD) in ALL

L. Foroni, M. Cole‐Sinclair, L. Coyle, 1996, British journal of haematology.

Imatinib‐induced cytogenetic remission in chronic eosinophilic leukaemia

D. Joske, B. Augustson, P. Cannell, 2006, Internal medicine journal.

Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients

B. George, G. Kennedy, A. Bryant, 2014, Bone Marrow Transplantation.

Translocation (X;20) involving the inactive X chromosome in a patient with myeloproliferative disorder.

J. O'Reilly, J. Crawford, P. Cannell, 2005, Cancer genetics and cytogenetics.

Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma

R. Greil, M. Dimopoulos, P. Sonneveld, 2019, Annals of Hematology.

Exacerbation of coagulopathy with concurrent bone marrow necrosis, hepatic and renal dysfunction secondary to all‐trans retinoic acid therapy for acute promyelocytic leukemia

J. Eikelboom, P. Cannell, G. Cull, 1997, Hematological oncology.

QuantiFERON‐cytomegalovirus to predict clinically significant cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation

M. John, Grace Thompson, D. Purtill, 2022, Transplant infectious disease : an official journal of the Transplantation Society.

Urate metabolism during bone marrow transplantation.

P. Cannell, R. Herrmann, 1992, Bone marrow transplantation.

High dose valaciclovir to prevent cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients

P. Polistena, D. Purtill, P. Boan, 2021, Transplant infectious disease : an official journal of the Transplantation Society.

H. Dombret, J. Franklin, A. Schuh, 2018, Blood.

Plasma lipids are altered in Gaucher disease: biochemical markers to evaluate therapeutic intervention.

P. Meikle, J. Hopwood, D. Elstein, 2008, Blood cells, molecules & diseases.

Collection and recruitment of CD34+ cells during large-volume leukapheresis.

P. Cannell, G. Cull, R. Herrmann, 1997, Journal of hematotherapy.

Red cell and platelet transfusion burden following myeloablative allogeneic haemopoietic stem cell transplantation

D. Purtill, J. Cooney, M. Wright, 2015, Internal medicine journal.

A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis.

P. Brooks, J. Snowden, G. McColl, 2002, Arthritis and rheumatism.

Acute graft‐versus‐host disease after liver transplant: Novel use of etanercept and the role of tumor necrosis factor α inhibitors

G. Garas, L. Adams, G. Jeffrey, 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Evaluating the Efficacy, Toxicity and Pharmacokinetic Profile of Oral Busulfan in Allogeneic Stem Cell Transplant Patients

Matthew P Wright, S. Salman, D. Purtill, 2022, Blood cell therapy.

Safety and efficacy results from an international Expanded Access Programme to bortezomib for patients with relapsed and/or refractory multiple myeloma: a subset analysis of the Australian and New Zealand data of 111 patients

H. Prince, J. Mikhael, B. Butcher, 2009, Internal medicine journal.

Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study

M. Dimopoulos, S. Harrison, P. Browett, 2017, British journal of haematology.

A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine.

J. Szer, J. Matthews, A. Schwarer, 2005, Blood.

Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR.

P. Brooks, P. Emery, J. Snowden, 2004, The Journal of rheumatology.

Recruitment of CD34+ cells during large‐volume leukapheresis

P. Cannell, G. Cull, 1997, Transfusion.

Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results

M. Millward, P. Mainwaring, M. Trikha, 2016, Clinical Cancer Research.

RESULTS OF A PHASE 3 RANDOMIZED CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF IDELALISIB (IDELA) IN COMBINATION WITH OFATUMUMAB (OFA) FOR PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Jeffrey A Jones, F. Bosch, P. Feugier, 2015 .

Outcomes from the first five years of allogeneic haemopoietic progenitor cell transplantation at Fiona Stanley Hospital

P. Chiappini, D. Purtill, J. Cooney, 2020 .

Blinatumomab consolidation and maintenance therapy in adults with relapsed/refractory B-precursor acute lymphoblastic leukemia.

J. Franklin, A. Rambaldi, P. Žák, 2020, Blood advances.

Outcomes After Unrelated Cord Blood Transplantation For Adults With Primary Or Secondary Myelofibrosis: A Retrospective Study On Behalf Of Eurocord and Chronic Malignancy Working Party-EBMT

N. Kröger, J. Sierra, M. Robin, 2013 .

Complete remission of stage IV erythrodermic mycosis fungoides with large cell transformation through combination of pralatrexate and romidepsin followed by allogeneic hematopoietic stem cell transplantation

D. Spagnolo, P. Cannell, Katherine Creeper, 2021, The Australasian journal of dermatology.

H. Dombret, J. Franklin, A. Schuh, 2016 .

Dasatinib therapy for systemic mastocytosis: four cases

R. Sinniah, D. Purtill, B. Augustson, 2008, European journal of haematology.

Specialist pharmacist consultations with cancer patients in a pharmacist‐led anticancer clinic

B. Sunderland, P. Czarniak, P. Cannell, 2022, Asia-Pacific journal of clinical oncology.

Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)

C. Hofmeister, A. Jakubowiak, T. Zimmerman, 2011 .

When the safety net of treatment has been removed: patients' unmet needs at the completion of treatment for haematological malignancies.

P. Butow, E. Lobb, L. Kristjanson, 2009, Patient education and counseling.

Oral Abstract: MM-459 Safety and Clinical Activity of Belantamab Mafodotin with Lenalidomide Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis

J. Opalinska, M. Gironella, N. Patel, 2022, Clinical Lymphoma Myeloma and Leukemia.

Prolonged profound abciximab associated immune thrombocytopenia complicated by transient multispecific platelet antibodies

P. Cannell, J. Lown, A. Hughes, 2004, Heart.

IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA IN THE RANDOMISED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN

W. Hiddemann, J. Radford, R. Marcus, 2017 .

Erdheim–Chester disease associated with a novel, complex BRAF p.Thr599_Val600delinsArgGlu mutation

M. Arooj, E. Gray, J. Bentel, 2017, BMJ Case Reports.

Bariatric surgery and allogeneic hematopoietic stem cell transplantation: a case series

D. Purtill, J. Cooney, M. Wright, 2023, Bone Marrow Transplantation.

A phase II study of risk‐adapted intravenous melphalan in patients with AL amyloidosis

S. Paul, C. Tiley, H. Prince, 2012, British journal of haematology.

Blinatumomab Alternating With Low-Intensity Chemotherapy (CT) Treatment for Older Adults With Newly Diagnosed Philadelphia (Ph)-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) is Well Tolerated and Efficacious: Safety Run-In Results for the Phase 3 Randomized Controlled Golden Gate

E. Jabbour, I. Aldoss, S. Fleming, 2022, Blood.

P. Marlton, J. Matthews, P. Browett, 2014, American journal of hematology.

Correlation of bone marrow minimal residual disease and apparent isolated extramedullary relapse in childhood acute lymphoblastic leukaemia.

R. Herrmann, B. Meyer, D. Baker, 1995, Leukemia.

N. Kröger, J. Sierra, M. Robin, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.